MedGenome

MedGenome is a genomics and genetic diagnostics company serving India, Southeast Asia, Africa and the US. The company operates South Asia’s largest CAP-accredited genetic testing laboratory, offering over 1,300 advanced genetic tests across oncology, rare diseases, reproductive health and infectious diseases. MedGenome’s integrated platform combines proprietary bioinformatics, high-throughput sequencing, and a vast clinico-genomic dataset, enabling it to deliver cutting-edge diagnostics and research services to hospitals, clinicians, pharma and research institutions. With more than 350,000 exomes and genomes sequenced and a robust global presence, MedGenome is recognized for its innovation in precision medicine, population genomics and multiomics research, positioning it as a transformative force in the field of genomics-driven healthcare.

 Core Products and Services

• Genetic Testing Portfolio: Offers 1,300+ genetic tests across oncology, neurology, cardiology, reproductive genetics, rare diseases and infectious diseases.

• CLARIA: Reproductive genetics (NIPT, carrier screening)

• ACTIA: Inherited disease genetics (clinical exome, rare disease panels)

• PRIMA: Cancer genetics (hereditary cancer panels, liquid biopsy)

• MICRA: Infectious disease genetics (TB, COVID-19, metagenomics)

• Genessense: D2C preventive wellness (polygenic risk scores for common diseases).

• Research and Multiomics Services: Provides whole genome/exome sequencing, transcriptomics, proteomics, epigenomics and advanced bioinformatics for pharma, biotech, and academic clients.

Business Model & Revenue Streams

• Clinical Diagnostics: Revenue from genetic testing services for hospitals, clinicians, and direct-to-consumer (D2C) wellness products. This segment covers the majority of revenue in India and Asia.

• Research Services: Revenue from genomics research, sequencing and bioinformatics for global pharma, biotech and academic clients. Project-based research, especially for US-based pharmaceutical clients, accounts for a significant share of international revenue.

• Revenue Contribution: Estimated annual revenue of $300 million as of 2025, with clinical diagnostics and research services as primary contributors.

Customer Segmentation

• B2B: Hospitals, clinicians, pharma/biotech companies, academic research labs.

• B2C: Patients and consumers seeking preventive wellness and genetic risk assessment.

• Geographic Mix: India remains the largest market, with growing presence in Southeast Asia, Africa and the US.

Top Clients & Partnerships

• Hospitals and Clinicians: Over 5,000 hospitals and 15,000 clinicians in India and abroad rely on MedGenome for advanced diagnostics.

• Pharma and Biotech: Strategic partnerships with global pharma for biomarker discovery, drug development, and clinical trials.

• Academic and Research Institutions: Collaborations with GenomeAsia 100K, Emmes (rare disease research), and government labs for population genomics and disease studies.

• Technology and Lab Partners: Partnerships with Illumina (sequencing platforms), Golden Helix (bioinformatics), and Twist Bioscience (rare disease diagnostics).

• Recent Acquisitions: Prognosis Laboratories (Delhi-NCR) and GenX Diagnostics (Odisha) to expand regional access and integrated diagnostics.

Future Outlook & Strategic Priorities

• Integrated Diagnostics Expansion: Aggressively expanding pan-India and internationally, with a focus on Tier 2/3 cities and emerging markets in Southeast Asia, Africa, and Latin America.

• Product Innovation: Launching new tests in preventive wellness (polygenic risk scores), rare diseases, and oncology. Continued investment in AI, machine learning, and multiomics for advanced diagnostics and drug discovery.

• M&A Pipeline: Ongoing acquisitions and partnerships to strengthen lab network, technology, and market reach (reflecting recent market trends).

• Regulatory and Pricing Pressures: Changes in diagnostics regulations, pricing controls, and quality standards could impact margins and compliance costs.

• Macroeconomic Volatility: Economic downturns may affect discretionary health spending, especially in non-metro markets.